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Background: The purpose of this study was to examine the usefulness of the conserved block 9 (CB9) to interspecies
conserved block (ICB10) region of Plasmodium vivax merozoite surface protein-1 (MSP-1 (ICB910)) as a serodiagnostic
tool for understanding malaria transmission.
Methods: Antibody titre in the blood samples collected from the inhabitants of Gimpo city, Paju city and Yeoncheon
county of Gyeonggi Province, as well as Cheorwon county of Gangwon Province, South Korea were determined by
enzyme-linked immunosorbent assay (ELISA). Microscopic examination was performed to identify malarial parasites.
Results: MSP-1(ICB910) is encoded by a 1,212-bp sequence, which produced a recombinant protein with a molecular
weight of approximately 46 kDa. Antibody titres in 1,774 blood samples were determined with the help of ELISA using
purified recombinant MSP-1(ICB910). The overall ELISA-positive rate was 8.08% (n = 146). The annual parasite incidences
(APIs) in the regions where the blood sampling was carried out gradually decreased from 2004 to 2005 (1.09 and 0.80,
respectively). Yeoncheon county had the highest ELISA-positive rate (10.20%, 46/451). Yeoncheon county also had the
highest API both in 2004 and 2005, followed by Cheorwon county, Paju city and Gimpo city.
Conclusions: The MSP-1 (ICB910)-ELISA-positive rates were closely related to API in the geographic areas studied.
These results suggest that sero-epidemiological studies employing MSP-1 (ICB910)-ELISA may be helpful in estimating
the prevalence of malaria in certain geographic areas. MSP-1(ICB910)-ELISA can be effectively used to establish and
evaluate malaria control and eradication programmes in the affected areas.Background
Plasmodium vivax causes the relapse of benign tertian
human malaria that affects several hundred millions of
individuals annually. This disease is a major public health
concern in most tropical and many temperate regions,
including North and South Korea [1]. The first scientific
documentation of malaria occurrence was published in
1913 [2]. A national malaria eradication programme* Correspondence: yjkang@jwu.ac.kr; rainlee67@naver.com
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unless otherwise stated.strengthened by the involvement of the World Health
Organization has succeeded in significantly reducing
the incidence of malaria in South Korea [3,4]. Malaria
was thought to have been eradicated in South Korea in
the late 1970s until two sporadic cases were detected
in the 1980s [5]. In 1993, a case was diagnosed among
South Korean soldiers serving in Northern Gyeonggi
Province [6]. Subsequently, Cho et al. reported two
instances of infected civilians [7]. Thereafter, many new
cases have been reported near the demilitarized zone
(DMZ): in Paju, Yeoncheon, Cheorwon, Gimpo, Ganghwa,
Goyang, and Dongducheon. The increasing number of
new cases raises the concern that malaria will become
re-established in the region [8,9].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of Health (KNIH) has developed a new diagnostic method
to support pathological examinations. This antibody-
based detection method uses merozoite surface protein-1
(MSP-1), an antigen and a large (180–230 kDa) glycopro-
tein that is synthesized as a precursor to MSP during
schizogony [10]. Comparisons of the sequences of MSP-1
from Plasmodium vivax, Plasmodium falciparum and
Plasmodium yoelii revealed the existence of ten interspecies
conserved blocks (ICBs) containing eight polymorphic
regions [11]. Serological surveys have provided valuable
epidemiological information, particularly in the areas of
low endemicity [12]. Estimation of the rate of parasitaemia
is the classical method of measuring the prevalence of
malaria. However, the incidence of parasitaemia alone
may fail to adequately describe the epidemiology of mal-
aria within a given population. For instance, when the
incidence of malaria is low, mass blood surveys do not
yield results commensurate with the work involved
[13,14]. In this study, the anti-P. vivax MSP-1 antibody
levels (particularly against the CB9 to ICB10 region)
among the populations of Gimpo, Paju, Yeoncheon, and
Cheorwon were determined to evaluate the usefulness
of the recombinant MSP-1(ICB910) antigen for assessing
the local malaria prevalence.
Methods
Blood samples of inhabitants
To evaluate the usefulness of the recombinant MSP-1
(ICB910) protein in serodiagnosis, blood samples were ob-
tained from the KNIH of the Korean Center for Disease
Control and Prevention (KCDC). These blood samples
(from 1,774 individuals) were collected from Gimpo and
Paju cities, Yeoncheon county of Gyeonggi Province, and
Cheorwon of Gangwon Province of South Korea, from
November to December of 2004 (Figure 1), and were
stored at the KNIH. Blood smears were also obtained
from the KNIH for microscopic examination.
Ethics statement
This study was conducted after receiving the written
informed consent from all participants and only after
receiving approval from the KNIH. The study procedures,
potential risks and benefits were explained to all of them.
Further, all data were analysed anonymously and patients
were not identified by name. This study was conducted
strictly adhering to the principles expressed in the Declar-
ation of Helsinki.
Microscopic examination
Thin blood films were prepared to determine the infect-
ivity of blood samples. The blood films were fixed with
methanol and stained with Giemsa stain to reveal the
parasite inclusions in the red blood cells (RBCs). Thinblood films are often preferred for routine estimation of
parasitaemia because the organisms can be readily visual-
ized and quantified with this method [15]. To estimate the
densities of blood-stage parasites by microscopy, the num-
ber of asexual parasites observed per 200 white blood cells
(WBCs) was determined, which was then multiplied by
the assumed number of WBCs per microlitre of blood
(8,000) [16].Amplification of the MSP-1 gene
To express the CB9 to ICB10 region of the P. vivax
MSP-1 gene, genomic DNA was extracted from the
whole blood of a patient diagnosed with malaria using
a QIAamp Blood Kit (Qiagen, Hilden, Germany). The
polymerase chain reaction (PCR) mixture contained
AccuPower PCR PreMix (Bioneer, Daejeon, Korea), 50 ng
of purified genomic DNA, and 40 pmoles each of forward
(MSP-910 F; 5′-ggatccGAAGACCAAGTAACAACGGG
AGAG-3′) and reverse (MSP-910R; 5′-aagcttTTAAAGCT
CCATGCACAGGAG-3′) primer (Figure 2). The total
volume of the reaction mixture was adjusted to 50 μL
with distilled water. The thermal cycling conditions were
as follows: denaturation at 94°C for 5 min; 35 cycles of
30 sec at 94°C, 60 sec at 55°C, and 45 sec at 72°C; and a
final incubation at 72°C for 5 min. All PCR products were
analysed by agarose gel electrophoresis on a 1% agarose
gel, visualized under an ultraviolet transilluminator, and
purified using a NucleoSpin Extract Kit (Macherey-Nagel;
Duren, Germany).DNA sequencing and analysis
To genotype the MSP-1(ICB910) gene of P. vivax, the
MSP-1(ICB910) gene was PCR-amplified and ligated
into a pCR2.1 vector (Invitrogen, Carlsbad, CA, USA)
and transformed into Escherichia coli TOP10 cells.
The E. coli TOP10 cells containing the recombinant
plasmid were selected in medium containing ampicillin
[17]. Plasmids were purified using a Qiagen plasmid
isolation kit according to the manufacturer’s protocols.
The transformants were confirmed by agarose gel elec-
trophoresis following restriction digestion with EcoRI.
The MSP-1(ICB910) gene sequence was determined using
an ABI PRISM Dye Terminator Cycle Sequencing Ready
Reaction Kit FS (Perkin Elmer, Cambridge, MA, USA)
following manufacturer’s instructions. M13 reverse and
forward (−20) primers were used for sequencing. Nucleo-
tide and deduced amino acid sequences were analysed
using EditSeq and Clustal in the MegAlign program, a
multiple alignment program within the DNASTAR pack-
age (DNASTAR, Madison, WI, USA). The internet-based
BLAST search program of the National Center for Bio-
technology Information was used to search protein
databases.
Figure 2 Nucleotide and amino acid sequences of Plasmodium vivax merozoite surface protein-1(ICB910). The nucleotide sequence was


































































Figure 1 Blood sample collection areas according to administrative districts. (A) Gimpo, (B) Paju, (C) Yeoncheon, (D) Cheorwon. a,
Haseongmyeon; b, Wolgotmyeon; c, Yangchonmyeon; d, Papyeongmyeon; e, Munsaneup; f, Baekhakmyeon; g, Wangjingmyeon; h, Misanmyeon;
i, Gimhwaeup; j, Seomyeon; k, Cheorwoneup; l, Geunnammyeon.
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To express the MSP-1 gene in E. coli DH5α cells, the
CB9 to ICB10 region of the MSP-1 gene fragment was
amplified using MSP-910 F and MSP-910R primers
(respectively containing BamHI and HindIII sites at
their 5′ ends) from a blood sample that was confirmed to
be infected with the dormant type of P. vivax (Figure 2).
The amplified-PCR products were digested with BamHI
and HindIII, the products were gel-purified using a
Qiagen gel extraction kit, and were ligated between the
BamHI and HindIII cleavage sites of the pQE30 expres-
sion vector (Qiagen). The resulting plasmid was used for
the expression of a MSP-1(ICB910)-(His)6 fusion protein
in E. coli cells. The transformants were first confirmed by
agarose gel electrophoresis following restriction digestion
using BamHI and HindIII. Finally, the insert sequence was
confirmed by DNA sequencing.
Expression and purification of recombinant MSP-1(ICB910)
The expression of the recombinant MSP-1(ICB910)-(His)6
fusion protein in E. coli DH5α cells was induced with
isopropyl-1-thio-β-D-galactopyranoside (IPTG) [18]. The
MSP-1(ICB910)-(His)6 fusion protein was purified using
immobilized metal ion affinity chromatography [19] under
native conditions following the manufacturer’s protocols
(Qiagen). Protein levels were analysed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
after each purification step.
Western blot analysis
The recombinant MSP-1(ICB910)-(His)6 fusion protein
was separated by SDS-PAGE on a 12% gel and transferred
onto a nitrocellulose membrane. After the transfer, the
membrane was cut into strips and blocked for nonspecific
binding with 3% skim milk for 12 hr at 4°C. The mem-
brane was then washed three times for 10 min each with
0.15% Tween 20 in phosphate-buffered saline (PBS). Fol-
lowing this, the strips were allowed to react for 4 hr with
sera from patients with malaria or from uninfected indi-
viduals (diluted 1:100, vol/vol). The membranes were then
washed three times for 10 min each with 0.15% Tween 20
in PBS and were subsequently incubated with peroxidase-
conjugated goat anti-human IgG secondary antibody
(1:1,000) (Sigma) for 3 hr at room temperature. For
colour development, a solution containing 0.2% diami-
nobenzidine and 0.02% H2O2/PBS was applied to each
well [20,21].
Enzyme-linked immunosorbent assay (ELISA)
An ELISA was used to determine whether the blood
samples contained antibodies against MSP-1(ICB910)
antigens. Briefly, the capture antigen solution (50 μL,
0.5 μg/mL) was placed in a 96-well plate (Corning, Lowell,
MA, USA) and incubated for 12 hr at room temperature.The antigen solution was then aspirated, blocking buffer
(1% bovine serum albumin, 0.05% PBS-Tween 20) was
added to each well, and the plate was incubated for 1 hr at
room temperature. After the wells were washed three times
with 0.05% Tween 20/PBS, human serum samples in block-
ing buffer at a dilution of 1:100 (vol/vol) were added to the
wells. Four positive and four negative control serum sam-
ples were also included in each plate. After incubating at
room temperature for 2 hr, the plates were washed with
0.05% Tween 20/PBS three times. Peroxidase-conjugated
anti-human IgG (Sigma, 1:2,000, vol/vol) diluted in block-
ing buffer was then added to each well and the plates were
incubated for 1 hr at room temperature. Following this, the
reaction was stopped by washing the plates as described
above. To develop the colour, 100 mL of 2,2′-azino-di-(3-
ethyl-benzthiozoline-6-sulphonic acid) (ABTS) peroxidase
substrate (Kirkegaard & Perry Laboratories, Gaithersburg,
MD, USA) was added to each well and the plates were in-
cubated for 30 min. This was followed by measuring the
absorbance of the solution at 405 nm. Cut-off value for
ELISA-positivity was defined as the sum total of the mean
values and two times the standard deviations of the nega-
tive control samples.Estimation of the annual parasite incidence (API)
For each of the study sites, the annual parasite incidence
(API) was calculated as the number of malaria-positive
patients per 1,000 inhabitants; API = (number of positive
slides/total number of slides) × 1,000.Data analysis
The data were analysed using Graphpad Prism software
version 4.0 (GraphPad Software Inc., La Jolla, CA, USA).
Pearson’s correlation analysis was performed to examine
the relationship between seropositivity and the API of P.
vivax in a given year. The data were analysed using SPSS
software, version 17.0 (SPSS Inc., Chicago, IL, USA). A
P-value of <0.05 indicated statistical significance. The
correlation sizes were interpreted as none (0.0-0.09), small
(0.1-0.3), medium (0.3-0.5), or strong (0.5-1.0) [22].Results
Blood sampling
The study locations are shown on the map in Figure 1.
All areas were near the DMZ, a known high-risk area.
Blood samples were collected from participants residing
in 23 villages and three cities (Gimpo, Paju and Yeoncheon)
located in Gyeonggi Province and six villages in Cheorwon
of Gangwon Province, South Korea. A total of 1,774 blood
samples (1.92%) were collected. The total number of
inhabitants in the geographical areas where the study
was conducted in the year 2004 was 92,246.
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(Korean isolate)
The region from CB9 to ICB10 of the MSP-1 gene that
was PCR-amplified from the genomic DNA was analysed
on a 1.0% agarose gel. Amplification of the MSP-1(ICB910)
gene yielded an approximately 1,200-bp DNA fragment
that was then ligated to the pCR2.1 cloning vector. Re-
striction analysis using EcoRI confirmed the identity of
the transformants. The plasmid containing the PCR
product was named pMSP910 and was subjected to
DNA sequence analysis. DNA sequencing revealed that
the cloned MSP-1(ICB910) gene was 1,212-bp in length
and encoded 403 amino acids as identified by DNASIS
(Figure 2, Genbank accession No KJ513462).
Expression of MSP-1(ICB910) in Escherichia coli and its
antigenicity
To construct the expression plasmid, the MSP-1(ICB910)
gene was amplified from the patient’s genomic DNA,
digested with BamHI and HindIII, and subcloned into the
same restriction enzyme sites of the pQE30 expression
vector to produce pMSPex910 containing a (His)6-tag.
The recombinant pMSPex910 plasmid was then transferred
into E. coli DH5α cells. For protein expression, 1 mM IPTG
was added to E. coli DH5α (pMSPex910) cells grown to
logarithmic phase in liquid Luria-Bertani medium con-
taining 100 μg/mL ampicillin and 50 μg/mL kanamycin
to induce the expression. SDS-PAGE followed by Coo-
massie blue staining showed that under native purification
conditions, the molecular weight of the recombinant
MSP-1(ICB910) protein was ~46 kDa (Figure 3A). The
antigenicity of the MSP-1(ICB910) recombinant protein
was determined by Western blot. The sera from patients
with malaria reacted positively (Figure 3B, No 1–3). One
sample (Figure 3B, No 6), which was collected from an in-
dividual who had no symptoms of infection, showed weak
positivity. During the follow-up study, this case became ill
four months after the blood sampling and was diagnosed
with vivax infection. To determine the sensitivity and
specificity of the MSP-1(ICB910) recombinant protein by
ELISA, the sera of patients with malaria were used. Sera
from 68 of the 70 patients with malaria (sensitivity, 97.1%)
were ELISA-positive, whereas all samples in the normal
control group (n = 8) were ELISA-negative (specificity,
100%) (Figure 3C).
Overview of malaria transmission in four locations
One-hundred and forty-six of the 1,774 study sub-
jects (8.23%) showed MSP-1(ICB910)-ELISA positivity.
Yeoncheon presented the highest positive rate (Figure 1C,
46/451, 10.20%), followed by Paju (Figure 1B, 35/372,
9.41%), Cheorwon (Figure 1D, 44/526, 8.37%), and Gimpo
(Figure 1A, 21/425, 4.94%). The 2004 API was higher
than the 2005 API. API did not vary within the samegeographic location during the years 2004 and 2005.
Yeoncheon presented the highest API in both years,
followed by Cheorwon, Paju and Gimpo. The seroposi-
tivity for the year 2004 showed a strong positive linear
relationship with the APIs of 2004 and 2005 (r = 0.691
and r = 0.842, respectively), but was statistically in-
significant (Table 1).
Local malaria transmission in Gimpo
Twenty-one of the 425 inhabitants (4.94%) presented
a positive response in MSP-1(ICB910)-ELISA. Haseong-
myeon presented the highest ELISA-positive rate (Figure 1a,
6/53, 11.32%), followed by Yangchonmyeon (Figure 1c,
10/206, 4.85%) and Wolgotmyeon (Figure 1b, 5/166,
3.01%). Wolgotmyeon presented the highest API in
2004 (1.42) and 2005 (0.71). Haseongmyeon presented
the second highest API in 2004 (0.69), but there were
no new diagnoses in 2005. Yangchonmyeon was third in
API in 2004 (0.50) and second in the year 2005 (0.25).
The seropositivity in 2004 showed a strong negative linear
relationship with the APIs of the years 2004 and 2005
(r = −0.513, r = −0.887, respectively). However, these
correlations were not statistically significant (Table 2).
Local malaria transmission in Paju
Thirty-five of the 372 inhabitants (9.41%) showed an
ELISA-positive response. Musaneup had a higher positive
rate (Figure 1e, 28/232, 12.07%) than Papyeongmyeon
(Figure 1d, 7/140, 5.00%). Papyeongmyeon had a
higher API than Munsaneup in the years 2004 and
2005. The seropositivity in 2004 showed a strong nega-
tive linear relationship with the APIs of 2004 and 2005
(r = −1.000 and r = −1.000, respectively). This result was
statistically significant (P = 0.01 for each year, Table 3).
Local malaria transmission in Yeoncheon-gun
Forty-six of the 451 inhabitants (10.20%) of Yeoncheon-gun
showed an ELISA-positive response. Misanmyeon had
the highest positive rate (Figure 1h, 9/75, 12.00%),
followed by Baekhakmyeon (Figure 1f, 28/265, 10.57%) and
Wangjingmyeon (Figure 1g, 9/111, 8.11%). Baekhakmyeon
had the highest API in 2004 (3.69) and dropped to third
place in 2005 (1.34). Misanmyeon had the second high-
est API in 2004 (2.79) and ranked first in 2005 (2.79).
Wangjingmyeon had the lowest API in 2004 (1.60) and
ranked second in 2005 (2.40). The seropositivity in 2004
showed a strong positive linear relationship with the
API of 2004 (r = 0.685) and a weak linear relationship
with API of 2005 (r = 0.111). However, these results
were statistically insignificant (Table 4).
Local malaria transmission in Cheorwon
Forty-four of the 526 inhabitants (8.37%) of Cheorwon



































Figure 3 Characterization of recombinant merozoite surface protein-1 (ICB910). (A) Purification of recombinant MSP-1 (ICB910) by Ni-NTA
agarose affinity chromatography. Lane M, molecular weight marker; lane 1, E. coli DH5α cell lysate after protein expression was induced with IPTG;
lane 2, flow-through; lane 3, wash; lane 4, eluted fraction. (B) Western blot analysis of recombinant MSP-1(ICB910) protein. Lanes 1–3, samples
from patients infected with malaria; Lanes 4–7, samples from uninfected individuals. (C) Immune responses of recombinant MSP-1(ICB910) to
vivax malaria patient group and normal person by Enzyme linked immunosorbent assay.
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11.97%), followed by Geunnammyeon (Figure 1l, 15/143,
10.49%), Gimhwaeup (Figure 1i, 12/115, 10.43%) and
Seomyeon (Figure 1j, 0/126, 0.00%). Seomyeon had the
highest API in 2004 (1.98), followed by Gimhwaeup
(1.54), Cheorwoneup (0.86) and Geunnammyeon (0.45).
However, Gimhwaeup had the highest API in 2005,
followed by Geunnammyeon (2.23), Seomyeon (0.49)
and Cheorwoneup (0.35). The seropositivity in 2004
showed a strong negative linear relationship with an APITable 1 Rates of MSP-1(ICB910)-ELISA positivity and annual
parasite incidence







Gimpo 425 21 4.94 0.73 0.28
Paju 372 35 9.41 1.07 0.86
Yeoncheon 451 46 10.20 2.99 1.99
Cheorwon 526 44 8.37 1.13 1.20
Total 1774 146 8.23 1.48 1.08
aAPI; Annual parasite incidence.
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2004 (r = 0.691, P = 0.309).
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2005 (r = 0.842, P = 0.158).of 2004 (r = −0.762) and a strong positive linear relation-
ship with API of 2005 (r = 0.430). However, these correla-
tions were statistically insignificant (Table 5).
Discussion
The areas surveyed, Gimpo, Paju, Yeoncheon, and
Cheorwon, which are located within 10–15 km of the
southern DMZ, are part of re-emerging malarial outbreak
areas in South Korea [8]. The DMZ is a 4 km-wide and
250 km-long corridor that extends across the middle part
of the Korean peninsula. Natural landscape, ecosystemsTable 2 Rates of MSP-1(ICB910)-ELISA positivity and
annual parasite incidence in Gimpo







Haseongmyeon 53 6 11.32 0.69 0.00
Yangchonmyeon 206 10 4.85 0.50 0.25
Wolgotmyeon 166 5 3.01 1.42 0.71
Total 425 21 4.94 0.87 0.49
aAPI; Annual parasite incidence.
-Correlation coefficient between MSP-1 (ICB910) positive rate of 2004 and API
of 2004 (r = −0.513, P = 0.657).
-Correlation coefficient between MSP-1 (ICB910) positive rate of 2004 and API
of 2005 (r = −0.887, P = 0.306).
Table 5 Rates of MSP-1(ICB910)-ELISA positivity and annual
parasite incidence in Cheorwon







Gimhwaeup 115 12 10.43 1.54 2.46
Seomyeon 126 0 0.00 7.98 0.49
Geunnammyeon 143 15 10.49 0.45 2.23
Cheorwoneup 142 17 11.97 0.86 0.35
Total 526 44 8.37 1.21 1.38
aAPI; Annual parasite incidence.
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2004 (r = −0.762, P = 0.238).
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2005 (r = 0.420, P = 0.580).
Table 3 Rates of MSP-1(ICB910)-ELISA positivity and
annual parasite incidence in Paju







Munsaneup 232 28 12.07 1.00 0.82
Papyeongmyeon 140 7 5.00 1.60 1.20
Total 372 35 9.41 1.31 1.01
aAPI; Annual parasite incidence.
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2004 (r = −1.000, P = 0.01).
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2005 (r = −1.000, P = 0.01).
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The outbreak areas expanded yearly both in the southern
and eastern directions from the DMZ in the initial stage
of re-emergence. Although there has been a sharp decline
in the reported cases in recent years, a re-emergence of
malaria in these areas cannot be ruled out. Effective con-
trol programmes will prevent the re-emergence of malaria.
Sensitive diagnostic tools that allow rapid and accurate
diagnosis will ensure the effectiveness of malaria preven-
tion and control programmes. MSP-1 is considered as a
useful antigen for serodiagnosis and is an important vac-
cine candidate against asexual blood stages [24-27]. The
MSP-1 protein binds to the surface of erythrocytes and is
one of the merozoite surface ligands involved in the inva-
sion of the erythrocytes. Comparison of the sequences of
MSP-1 proteins from P. vivax, P. falciparum, and P. yoelii
revealed seven ICBs (ICB1, ICB2, ICB4, ICB5, ICB6, ICB8,
and ICB10) and three CBs (CB3, CB7 and CB9) [11]. The
immune responses to the N- and C-terminal regions of
MSP-1 have been characterized [24]. The 11 regions of
MSP-1 expressed in E. coli were glutathione S-transferase
(GST) regions. It was reported that 83.3% of malaria
patients had IgG complexes against at least one of the
GST-fusion proteins. In addition, the frequency of
patients with the IgG antibodies to recombinant ICB10
protein, which contained only the 111 C-terminal amino
acids of MSP-1, increased with the number of P. vivaxTable 4 Rates of MSP-1(ICB910)-ELISA positivity and
annual parasite incidence in Yeoncheon







Wangjingmyeon 111 9 8.11 1.60 2.40
Baekhakmyeon 265 28 10.57 3.69 1.34
Misanmyeon 75 9 12.00 2.79 2.79
Total 451 46 10.20 2.69 2.18
aAPI; Annual parasite incidence.
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2004 (r = 0.685, P = 0.519).
-Correlation coefficient between MSP-1(ICB910) positive rate of 2004 and API
of 2005 (r = 0.111, P = 0.929).malaria experiences, reaching 83.3% after four experi-
ences. However, the responses to recombinant ICB2-5,
which consisted of 506 C-terminal amino acids of MSP-1,
did not have the same frequency. The titre of the antibody
against recombinant ICB10 protein was greater than that
of the antibody against recombinant ICB2-5. Furthermore,
ICB10 helps peripheral blood mononuclear cells (PBMCs)
to secrete IFN-γ, suggesting that T-cell epitopes are present
in this region. Soares et al. found that the C-terminal region
was immunogenic to both antibodies and T-cells were
produced following infections in humans [28]. MSP-1
could be a useful vaccine against P. vivax malaria because
the C-terminal region of MSP-1 is less polymorphic
than the N-terminal region [29] and the epitopes to B-
and T-cells have specific humoral responses that produce
longer-term stability [30]. Therefore, the region from CB9
to ICB10 of MSP-1 was selected and expressed as a re-
combinant protein in E. coli for use in sero-epidemiology.
In the present study, a recombinant MSP-1(ICB910)
antigen-based ELISA diagnostic method was used to
evaluate the antibody levels in the inhabitants of high-risk
areas. The incidence of malaria peaks in August after the
rainy season and declines to baseline by mid-October.
Therefore, blood sampling was carried out between late-
October and mid-December, when the active anopheline
population had diminished. Since ELISA-based screening
for the presence of an antibody could provide useful infor-
mation regarding P. vivax infection in a previously naïve
population, the significance between the positive rate and
incidence of malaria in high-risk areas were compared.
The MSP-1(ICB910)-ELISA-positive rates and the APIs
of four cities in both years showed strong linear relation-
ships, but were not statistically significant (P = 0.309 and
P = 0.158, respectively) (Table 1). The local transmission
in Gimpo showed a strong negative relationship between
API and MSP-1(ICB910)-ELISA, but it was not significant
(2004, P = 0.657; 2005, P = 0.306). Local transmission in
Paju showed a strong negative relationship between API
and MSP-1(ICB910)-ELISA that was statistically significant
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http://www.malariajournal.com/content/13/1/311(2004, P = 0.01; 2005, P = 0.01). Local transmission in
Yeoncheon showed strong relationship between the
API and MSP-1(ICB910)-ELISA of 2004 and a weak
relationship in 2005 (2004, P = 0.519; 2005, P = 0.929).
In Cheorwon, the MSP-1(ICB910)-ELISA response and
API had a strong negative relationship in 2004 (P = 0.238)
and a medium positive relationship in 2005 (P = 0.580).
These differences might be related to the different malaria
control programmes adopted in the areas. Malaria control
programmes are administered by four public health centres
(PHCs). Each PHC uses their own manual that takes the
local malaria prevalence and geographical characteristics
into account. While evaluating the malaria transmission in
a given geographical region, factors such as temperature,
mosquito density, vector capacity, climate, rainfall, and
humidity must be considered [31]. However, collecting
data requires much effort. Therefore, it is necessary to
establish a cost-effective tool to analyse the current and
future transmission of malaria in specific geographic
areas using serodiagnostic methods. Parasitaemia provides
a classical means for measuring malaria endemicity, but
patient incidence alone is unlikely to provide a complete
understanding of malaria prevalence. Factors including
the population density of mosquitoes, vectorial capacity,
long- to short-incubation patient ratio, symptomatic to
asymptomatic patient ratio, differences in rainfall and
temperature, and immunity of the community all affect
malaria prevalence in Korea. These results suggest that
antibody detection methods provide results that are
more valuable than API values obtained by microscopic
examination in certain circumstances. Such methods will
help to better understand malaria transmission in a given
geographical area.
Conclusions
The antibody detection method using MSP-1 (ICB910)-
ELISA provides useful information regarding malaria preva-
lence in specific geographical areas and individuals.
This serological method is useful for identifying areas
that require malaria control.
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